The matrix
Who covers a GLP-1, and where
Coverage depends on what kind of plan you have before it depends on where you live. Start with your plan type, then check your state.
- 10 of 50Covers for weight losspay for these drugs for weight loss, with prior authorization
- 33 of 50Other diagnoses onlyweight loss excluded; heart, liver or sleep apnea can qualify
- 6 of 50Does not coverweight loss excluded, and no other route named
- 1 of 50Depends on your planeach health plan sets its own list
By plan type
- Medicare Part DThe law still excludes weight-loss drugs. A separate CMS demonstration pays for some GLP-1s at a $50 monthly copay.
- MedicaidYour state decides. 10 of 50 cover these drugs for weight loss; 33 cover them only for other diagnoses.
- Employer and commercial plansLarge employers cover these drugs far more often than small ones. Your plan document settles it, not the drug.
State Medicaid, for obesity
Covers for weight loss 10 of 50 (pay for these drugs for weight loss, with prior authorization) — Michigan, North Carolina, Virginia, Mississippi, Missouri, Minnesota, Wisconsin, Kansas, Tennessee, Delaware
Other diagnoses only 33 of 50 (weight loss excluded; heart, liver or sleep apnea can qualify) — California, New York, Pennsylvania, Ohio, Texas, Washington, Arizona, Massachusetts, New Jersey, Utah, Colorado, Maryland, Indiana, South Carolina, Louisiana, Alabama, Kentucky, Oregon, Oklahoma, Connecticut, Rhode Island, Arkansas, Iowa, Maine, Montana, Nebraska, Nevada, New Hampshire, North Dakota, South Dakota, Vermont, West Virginia, Wyoming
Does not cover 6 of 50 (weight loss excluded, and no other route named) — Florida, Georgia, Illinois, Alaska, Idaho, New Mexico
Depends on your plan 1 of 50 (each health plan sets its own list) — Hawaii
Six columns on a wide screen. On a phone, this becomes one card per state, led by the appeal deadline.
| State | Medicaid, for obesity | What that means | Appeal deadline | Sources cited | |
|---|---|---|---|---|---|
| California | Other diagnoses only | Coverage for weight loss ended January 1, 2026. GLP-1s stay covered for other approved uses. | 90 days from the Notice of Action (start a hearing within 10 days to keep receiving the drug while it's decided) | 4 | Open |
| New York | Other diagnoses only | Weight loss has never been a covered reason. Two GLP-1s are covered for other uses, both behind a high BMI. | Source unreachable | 5 | Open |
| Pennsylvania | Other diagnoses only | Coverage for overweight and obesity ended January 1, 2026. Saxenda is no longer covered for anything. | 30 days from written notice (60 days where no written notice was required) | 3 | Open |
| Michigan | Covers for weight loss | Coverage survived January 1, 2026, but only for morbid obesity after every other treatment has failed. | 90 days from the written notice of case action | 4 | Open |
| Florida | Does not cover | Weight control medications are a named exclusion, in a coverage policy still dated December 2017. | 90 days (fee-for-service); 120 days after a plan appeal (managed care) | 5 | Open |
| Ohio | Other diagnoses only | Obesity is a coded exclusion no one can request around. Wegovy is covered for heart and liver disease, not weight. | 60 days to appeal to the plan, then 90 days from that decision to ask for a state hearing (managed care) | 5 | Open |
| North Carolina | Covers for weight loss | Cut October 1, 2025 and restored ten weeks later. Now on, behind a BMI floor and a 5% renewal test. | 30 days to the hearings office on NC Medicaid Direct; in managed care, 60 days to the plan then 120 days to the hearings office | 8 | Open |
| Georgia | Does not cover | Weight-loss agents are a named exclusion. The one open door is Saxenda for ages 12 to 17, and it shuts at 18. | 30 days from the date on the adverse action letter | 6 | Open |
| Texas | Other diagnoses only | Wegovy and Zepbound are covered, but obesity alone never qualifies — heart, liver or sleep apnea does. | 90 calendar days, from the effective date of the action or the notice date, whichever is later | 6 | Open |
| Illinois | Does not cover | Excluded by rule. The state's own criteria file Wegovy, Zepbound and Saxenda as not covered agents. | 60 days to appeal to the plan, then 120 days to a state fair hearing (10 days to keep your medicine meanwhile) | 7 | Open |
| Washington | Other diagnoses only | Excluded by rule for weight loss. Wegovy and Zepbound are covered only for heart, liver or sleep-apnea uses. | Managed care: 60 days to the plan, then 120 days to a state hearing. Agency notice: its own window | 10 | Open |
| Virginia | Covers for weight loss | Covered with conditions: a BMI over 40, or over 37 with a named condition, after an older weight-loss drug is tried. | Agency notice: 30 days from receipt. Managed care: 60 days to the plan, then 120 days to the state | 8 | Open |
| Arizona | Other diagnoses only | Excluded for weight loss. Wegovy is allowed for heart or liver disease; Zepbound for sleep apnea is denied. | Source unreachable | 5 | Open |
| Massachusetts | Other diagnoses only | Coverage for obesity ended July 3, 2026. Other approved uses stay covered; some members under 21 are excepted. | Agency notice: 60 days from receipt. Managed care: 120 days after the plan's final appeal decision | 7 | Open |
| New Jersey | Other diagnoses only | Excluded by rule for obesity; a 2025 state study left it there. Wegovy and Zepbound are covered for other uses. | Agency notice: 30 days from its date (20 from receipt). Managed care: the plan's appeal comes first | 6 | Open |
| Mississippi | Covers for weight loss | Covered with prior authorization. Zepbound and Foundayo joined the preferred list on July 1, 2026. | 30 days from the postmark on the notice; 10 days to keep a benefit running. Managed care appeals come first | 5 | Open |
| Missouri | Covers for weight loss | Covered since January 2025, with Zepbound preferred. Wegovy is not covered for weight loss itself. | 90 days from the notice to appeal a refusal; 10 days if the state is cutting something you already have | 7 | Open |
| Minnesota | Covers for weight loss | Covers Saxenda, Wegovy and Zepbound with prior authorization. Renewal needs 5% weight loss. | 30 days from the day you received the notice, or up to 90 days if the state accepts good cause | 3 | Open |
| Wisconsin | Covers for weight loss | A new weight management drug class opened July 1, 2026 with Zepbound preferred; eight older drugs dropped. | 45 days for a state decision; 90 days from receipt where a managed care plan upheld its own denial | 2 | Open |
| Utah | Other diagnoses only | Covered as a pilot from July 1, 2025 and ended June 30, 2026. Three comorbidity routes survive. | Source unreachable | 5 | Open |
| Colorado | Other diagnoses only | Weight loss is excluded by rule. Zepbound for sleep apnea and Wegovy for heart risk are the ways in. | 60 days from the date on the Notice of Action; 10 days to keep services running. Managed care plans come first | 5 | Open |
| Kansas | Covers for weight loss | Covers Wegovy and Zepbound as preferred. One statewide list binds all three KanCare plans. | 63 calendar days from the date on the notice, filed with your plan — not the state. 10 days to keep services running | 6 | Open |
| Maryland | Other diagnoses only | Weight control is excluded by regulation. Wegovy for heart risk and Zepbound for sleep apnea are covered. | Fee-for-service: 90 days from receiving the notice. Managed care: 60 days to the plan, then 120 days to the state | 8 | Open |
| Tennessee | Covers for weight loss | Covered since August 1, 2025. Wegovy and Zepbound are preferred; older appetite drugs need no approval. | None stated | 4 | Open |
| Indiana | Other diagnoses only | Excluded by rule for adults. Sleep apnea, heart risk and liver disease are the doors, and under-21 has its own. | 33 calendar days from the later of the date you received the decision or the date it takes effect. Managed care members appeal to their plan first | 6 | Open |
| Delaware | Covers for weight loss | Covers Wegovy and Zepbound as preferred, and has just moved the promise out of its State Plan. | 90 days from the date the action takes effect, and the hearing officer cannot extend it. Managed care members get 120 days from their plan's resolution notice | 5 | Open |
| South Carolina | Other diagnoses only | Removed GLP-1s for obesity from its drug list on December 31, 2025. Wegovy survives for heart and liver. | 30 calendar days following receipt of the notice, by postmark. 10 days from the date on the notice to keep services running | 7 | Open |
| Louisiana | Other diagnoses only | Covers Wegovy for heart and liver, Zepbound for sleep apnea, and makes the patient sign an agreement. | None stated | 6 | Open |
| Alabama | Other diagnoses only | Its drug list says it in a footnote: Wegovy and Zepbound are non-covered for weight reduction. | 60 days from the date the notice of action is mailed — and it must be received by Medicaid within that time, not merely posted | 4 | Open |
| Kentucky | Other diagnoses only | No anti-obesity class on its drug list at all. Wegovy and Zepbound have their own criteria instead. | 30 calendar days by postmark if the state denied you; 60 days to your plan if an MCO did, then 120 days to a state fair hearing | 6 | Open |
| Oregon | Other diagnoses only | Excludes these drugs from its Prioritized List of Health Services entirely, not from a drug list. | 60 days from the date on the notice, to your CCO or to OHA. 10 days from the effective date to keep a service running | 4 | Open |
| Oklahoma | Other diagnoses only | Calls the category adiposity-based chronic disease, then closes the obesity-alone door three times over. | Source unreachable | 2 | Open |
| Connecticut | Other diagnoses only | Gated the GLP-1s to diabetes, then added two cheap oral weight-loss drugs on the same day. | 60 days from the decision, and it has to be mailed — the statute counts from when the decision was made, not from when you opened the envelope | 7 | Open |
| Rhode Island | Other diagnoses only | From October 1, 2026, four GLP-1s are no longer covered for weight loss. Other uses need a new approval. | None stated | 7 | Open |
| Alaska | Does not cover | The pharmacy manual excludes obesity drugs by name; the statewide drug list carries GLP-1s for diabetes only. | 30 calendar days from the date on the notice | 4 | Open |
| Arkansas | Other diagnoses only | Weight loss alone is excluded; Wegovy is covered for heart risk and liver disease, Zepbound for sleep apnea. | 30 calendar days from the date of written notice, and the 30 days does not start counting until 5 days after that date | 5 | Open |
| Hawaii | Depends on your plan | Hawaii sets no statewide drug list; coverage depends on which of five QUEST health plans a member is in. | 90 calendar days from the date of the notice — and for a QUEST managed-care plan's own decision, only after you've finished that plan's own grievance and appeals process | 4 | Open |
| Idaho | Does not cover | No anti-obesity drug appears on the current statewide list; the diabetes GLP-1s are covered for diabetes only. | 28 calendar days from the date on the notice | 3 | Open |
| Iowa | Other diagnoses only | Wegovy and Zepbound are Preferred on the drug list, but its own footnote excludes the weight-loss indication. | 90 days from the date on the notice of decision if your Medicaid is fee-for-service; 120 days from your health plan's own appeal decision if you are in managed care | 5 | Open |
| Maine | Other diagnoses only | Wegovy is covered for heart risk and a liver condition, Zepbound for sleep apnea. Weight loss stays excluded. | 60 calendar days from the date of written notice | 3 | Open |
| Montana | Other diagnoses only | The standard drug list never names Wegovy or Zepbound; a separate pathway covers each for a non-obesity reason. | 90 days from the date the denial notice was mailed | 4 | Open |
| Nebraska | Other diagnoses only | Both drugs are off the standard list, each with its own pathway: Wegovy for heart risk, Zepbound for sleep apnea. | 60 days from the date on your denial notice to appeal to your health plan, then 120 days from that plan's decision to ask for a state fair hearing | 4 | Open |
| Nevada | Other diagnoses only | Weight-management drugs are excluded by the state manual. Wegovy for heart risk, Zepbound for sleep apnea. | 90 calendar days from the date on the notice of decision — but if you are in a managed care plan, you appeal to the plan first | 5 | Open |
| New Hampshire | Other diagnoses only | Weight-loss coverage ended January 1, 2026. Heart risk, sleep apnea and MASH survive. | 30 days from the date the department's notice of decision was issued — but a managed care member appeals to the plan first, on a longer clock | 9 | Open |
| New Mexico | Does not cover | The state's own page lists Wegovy, Zepbound and Saxenda as not covered by New Mexico Medicaid. | 90 calendar days from the date on the notice if you are not in a managed care plan; 30 days from the plan's final decision if you are | 7 | Open |
| North Dakota | Other diagnoses only | No obesity pathway at all. Wegovy only for heart risk, ages 55 to 74; Zepbound only for sleep apnea. | 30 days from the date the notice was mailed — or 120 days if a managed care plan has already upheld the denial. The state must receive it, not just have it postmarked, by then | 3 | Open |
| South Dakota | Other diagnoses only | Wegovy is MACE or MASH only and Zepbound OSA only. The drug list's own class name rules out weight loss. | 30 days from the notice of the action, filed with the state's Office of Administrative Hearings | 6 | Open |
| Vermont | Other diagnoses only | The drug list excludes weight-loss drugs up front. Wegovy for heart risk and Zepbound for sleep apnea are covered. | 60 calendar days to ask the Department to review the decision, then 120 days from that appeal decision letter to ask the Human Services Board for a fair hearing | 3 | Open |
| West Virginia | Other diagnoses only | Weight loss is a non-covered service. Wegovy covers heart risk and MASH; Zepbound covers sleep apnea. | 90 days from the effective date of the action — which is not the date printed on the notice | 5 | Open |
| Wyoming | Other diagnoses only | Anorexiant products are excluded outright. Wegovy needs heart disease or MASH; Zepbound needs sleep apnea. | 20 business days after the notice of adverse action is mailed — and a pharmacy denial has to go through reconsideration first | 4 | Open |
- 90 days from the Notice of Action (start a hearing within 10 days to keep receiving the drug while it's decided)CaliforniaOther diagnoses onlyCoverage for weight loss ended January 1, 2026. GLP-1s stay covered for other approved uses.4 sources cited · Open
- Deadline not publishedNew YorkOther diagnoses onlyWeight loss has never been a covered reason. Two GLP-1s are covered for other uses, both behind a high BMI.5 sources cited · Open
- 30 days from written notice (60 days where no written notice was required)PennsylvaniaOther diagnoses onlyCoverage for overweight and obesity ended January 1, 2026. Saxenda is no longer covered for anything.3 sources cited · Open
- 90 days from the written notice of case actionMichiganCovers for weight lossCoverage survived January 1, 2026, but only for morbid obesity after every other treatment has failed.4 sources cited · Open
- 90 days (fee-for-service); 120 days after a plan appeal (managed care)FloridaDoes not coverWeight control medications are a named exclusion, in a coverage policy still dated December 2017.5 sources cited · Open
- 60 days to appeal to the plan, then 90 days from that decision to ask for a state hearing (managed care)OhioOther diagnoses onlyObesity is a coded exclusion no one can request around. Wegovy is covered for heart and liver disease, not weight.5 sources cited · Open
- 30 days to the hearings office on NC Medicaid Direct; in managed care, 60 days to the plan then 120 days to the hearings officeNorth CarolinaCovers for weight lossCut October 1, 2025 and restored ten weeks later. Now on, behind a BMI floor and a 5% renewal test.8 sources cited · Open
- 30 days from the date on the adverse action letterGeorgiaDoes not coverWeight-loss agents are a named exclusion. The one open door is Saxenda for ages 12 to 17, and it shuts at 18.6 sources cited · Open
- 90 calendar days, from the effective date of the action or the notice date, whichever is laterTexasOther diagnoses onlyWegovy and Zepbound are covered, but obesity alone never qualifies — heart, liver or sleep apnea does.6 sources cited · Open
- 60 days to appeal to the plan, then 120 days to a state fair hearing (10 days to keep your medicine meanwhile)IllinoisDoes not coverExcluded by rule. The state's own criteria file Wegovy, Zepbound and Saxenda as not covered agents.7 sources cited · Open
- Managed care: 60 days to the plan, then 120 days to a state hearing. Agency notice: its own windowWashingtonOther diagnoses onlyExcluded by rule for weight loss. Wegovy and Zepbound are covered only for heart, liver or sleep-apnea uses.10 sources cited · Open
- Agency notice: 30 days from receipt. Managed care: 60 days to the plan, then 120 days to the stateVirginiaCovers for weight lossCovered with conditions: a BMI over 40, or over 37 with a named condition, after an older weight-loss drug is tried.8 sources cited · Open
- Deadline not publishedArizonaOther diagnoses onlyExcluded for weight loss. Wegovy is allowed for heart or liver disease; Zepbound for sleep apnea is denied.5 sources cited · Open
- Agency notice: 60 days from receipt. Managed care: 120 days after the plan's final appeal decisionMassachusettsOther diagnoses onlyCoverage for obesity ended July 3, 2026. Other approved uses stay covered; some members under 21 are excepted.7 sources cited · Open
- Agency notice: 30 days from its date (20 from receipt). Managed care: the plan's appeal comes firstNew JerseyOther diagnoses onlyExcluded by rule for obesity; a 2025 state study left it there. Wegovy and Zepbound are covered for other uses.6 sources cited · Open
- 30 days from the postmark on the notice; 10 days to keep a benefit running. Managed care appeals come firstMississippiCovers for weight lossCovered with prior authorization. Zepbound and Foundayo joined the preferred list on July 1, 2026.5 sources cited · Open
- 90 days from the notice to appeal a refusal; 10 days if the state is cutting something you already haveMissouriCovers for weight lossCovered since January 2025, with Zepbound preferred. Wegovy is not covered for weight loss itself.7 sources cited · Open
- 30 days from the day you received the notice, or up to 90 days if the state accepts good causeMinnesotaCovers for weight lossCovers Saxenda, Wegovy and Zepbound with prior authorization. Renewal needs 5% weight loss.3 sources cited · Open
- 45 days for a state decision; 90 days from receipt where a managed care plan upheld its own denialWisconsinCovers for weight lossA new weight management drug class opened July 1, 2026 with Zepbound preferred; eight older drugs dropped.2 sources cited · Open
- Deadline not publishedUtahOther diagnoses onlyCovered as a pilot from July 1, 2025 and ended June 30, 2026. Three comorbidity routes survive.5 sources cited · Open
- 60 days from the date on the Notice of Action; 10 days to keep services running. Managed care plans come firstColoradoOther diagnoses onlyWeight loss is excluded by rule. Zepbound for sleep apnea and Wegovy for heart risk are the ways in.5 sources cited · Open
- 63 calendar days from the date on the notice, filed with your plan — not the state. 10 days to keep services runningKansasCovers for weight lossCovers Wegovy and Zepbound as preferred. One statewide list binds all three KanCare plans.6 sources cited · Open
- Fee-for-service: 90 days from receiving the notice. Managed care: 60 days to the plan, then 120 days to the stateMarylandOther diagnoses onlyWeight control is excluded by regulation. Wegovy for heart risk and Zepbound for sleep apnea are covered.8 sources cited · Open
- Deadline not publishedTennesseeCovers for weight lossCovered since August 1, 2025. Wegovy and Zepbound are preferred; older appetite drugs need no approval.4 sources cited · Open
- 33 calendar days from the later of the date you received the decision or the date it takes effect. Managed care members appeal to their plan firstIndianaOther diagnoses onlyExcluded by rule for adults. Sleep apnea, heart risk and liver disease are the doors, and under-21 has its own.6 sources cited · Open
- 90 days from the date the action takes effect, and the hearing officer cannot extend it. Managed care members get 120 days from their plan's resolution noticeDelawareCovers for weight lossCovers Wegovy and Zepbound as preferred, and has just moved the promise out of its State Plan.5 sources cited · Open
- 30 calendar days following receipt of the notice, by postmark. 10 days from the date on the notice to keep services runningSouth CarolinaOther diagnoses onlyRemoved GLP-1s for obesity from its drug list on December 31, 2025. Wegovy survives for heart and liver.7 sources cited · Open
- Deadline not publishedLouisianaOther diagnoses onlyCovers Wegovy for heart and liver, Zepbound for sleep apnea, and makes the patient sign an agreement.6 sources cited · Open
- 60 days from the date the notice of action is mailed — and it must be received by Medicaid within that time, not merely postedAlabamaOther diagnoses onlyIts drug list says it in a footnote: Wegovy and Zepbound are non-covered for weight reduction.4 sources cited · Open
- 30 calendar days by postmark if the state denied you; 60 days to your plan if an MCO did, then 120 days to a state fair hearingKentuckyOther diagnoses onlyNo anti-obesity class on its drug list at all. Wegovy and Zepbound have their own criteria instead.6 sources cited · Open
- 60 days from the date on the notice, to your CCO or to OHA. 10 days from the effective date to keep a service runningOregonOther diagnoses onlyExcludes these drugs from its Prioritized List of Health Services entirely, not from a drug list.4 sources cited · Open
- Deadline not publishedOklahomaOther diagnoses onlyCalls the category adiposity-based chronic disease, then closes the obesity-alone door three times over.2 sources cited · Open
- 60 days from the decision, and it has to be mailed — the statute counts from when the decision was made, not from when you opened the envelopeConnecticutOther diagnoses onlyGated the GLP-1s to diabetes, then added two cheap oral weight-loss drugs on the same day.7 sources cited · Open
- Deadline not publishedRhode IslandOther diagnoses onlyFrom October 1, 2026, four GLP-1s are no longer covered for weight loss. Other uses need a new approval.7 sources cited · Open
- 30 calendar days from the date on the noticeAlaskaDoes not coverThe pharmacy manual excludes obesity drugs by name; the statewide drug list carries GLP-1s for diabetes only.4 sources cited · Open
- 30 calendar days from the date of written notice, and the 30 days does not start counting until 5 days after that dateArkansasOther diagnoses onlyWeight loss alone is excluded; Wegovy is covered for heart risk and liver disease, Zepbound for sleep apnea.5 sources cited · Open
- 90 calendar days from the date of the notice — and for a QUEST managed-care plan's own decision, only after you've finished that plan's own grievance and appeals processHawaiiDepends on your planHawaii sets no statewide drug list; coverage depends on which of five QUEST health plans a member is in.4 sources cited · Open
- 28 calendar days from the date on the noticeIdahoDoes not coverNo anti-obesity drug appears on the current statewide list; the diabetes GLP-1s are covered for diabetes only.3 sources cited · Open
- 90 days from the date on the notice of decision if your Medicaid is fee-for-service; 120 days from your health plan's own appeal decision if you are in managed careIowaOther diagnoses onlyWegovy and Zepbound are Preferred on the drug list, but its own footnote excludes the weight-loss indication.5 sources cited · Open
- 60 calendar days from the date of written noticeMaineOther diagnoses onlyWegovy is covered for heart risk and a liver condition, Zepbound for sleep apnea. Weight loss stays excluded.3 sources cited · Open
- 90 days from the date the denial notice was mailedMontanaOther diagnoses onlyThe standard drug list never names Wegovy or Zepbound; a separate pathway covers each for a non-obesity reason.4 sources cited · Open
- 60 days from the date on your denial notice to appeal to your health plan, then 120 days from that plan's decision to ask for a state fair hearingNebraskaOther diagnoses onlyBoth drugs are off the standard list, each with its own pathway: Wegovy for heart risk, Zepbound for sleep apnea.4 sources cited · Open
- 90 calendar days from the date on the notice of decision — but if you are in a managed care plan, you appeal to the plan firstNevadaOther diagnoses onlyWeight-management drugs are excluded by the state manual. Wegovy for heart risk, Zepbound for sleep apnea.5 sources cited · Open
- 30 days from the date the department's notice of decision was issued — but a managed care member appeals to the plan first, on a longer clockNew HampshireOther diagnoses onlyWeight-loss coverage ended January 1, 2026. Heart risk, sleep apnea and MASH survive.9 sources cited · Open
- 90 calendar days from the date on the notice if you are not in a managed care plan; 30 days from the plan's final decision if you areNew MexicoDoes not coverThe state's own page lists Wegovy, Zepbound and Saxenda as not covered by New Mexico Medicaid.7 sources cited · Open
- 30 days from the date the notice was mailed — or 120 days if a managed care plan has already upheld the denial. The state must receive it, not just have it postmarked, by thenNorth DakotaOther diagnoses onlyNo obesity pathway at all. Wegovy only for heart risk, ages 55 to 74; Zepbound only for sleep apnea.3 sources cited · Open
- 30 days from the notice of the action, filed with the state's Office of Administrative HearingsSouth DakotaOther diagnoses onlyWegovy is MACE or MASH only and Zepbound OSA only. The drug list's own class name rules out weight loss.6 sources cited · Open
- 60 calendar days to ask the Department to review the decision, then 120 days from that appeal decision letter to ask the Human Services Board for a fair hearingVermontOther diagnoses onlyThe drug list excludes weight-loss drugs up front. Wegovy for heart risk and Zepbound for sleep apnea are covered.3 sources cited · Open
- 90 days from the effective date of the action — which is not the date printed on the noticeWest VirginiaOther diagnoses onlyWeight loss is a non-covered service. Wegovy covers heart risk and MASH; Zepbound covers sleep apnea.5 sources cited · Open
- 20 business days after the notice of adverse action is mailed — and a pharmacy denial has to go through reconsideration firstWyomingOther diagnoses onlyAnorexiant products are excluded outright. Wegovy needs heart disease or MASH; Zepbound needs sleep apnea.4 sources cited · Open
Medicaid rules change with state budgets and preferred drug lists. Each state page carries the date its facts were read and links to the state's own document. "Sources cited" counts distinct documents, not distinct sentences — see each state page for the full list.
Wondering whether a rule was already in force on some particular day? The policy timeline splits every dated document in this corpus around a date you pick, and counts the months either side.
Denied already? Start here instead.